{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:16:53Z","timestamp":1794003413143,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2021YFC2501000"],"award-info":[{"award-number":["2021YFC2501000"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["CIFMS, 2021-I2M-1-018"],"award-info":[{"award-number":["CIFMS, 2021-I2M-1-018"]}]},{"name":"Potential Development Projects of Cancer Hospital, CAMS","award":["PY2018B01"],"award-info":[{"award-number":["PY2018B01"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81930077"],"award-info":[{"award-number":["81930077"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The mechanisms underlying the occurrence and development of esophageal squamous cell carcinoma (ESCC) remains to be elucidated. The present study aims to investigate the roles and implications of IGF2BP1 overexpression in ESCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      IGF2BP1 protein expression in ESCC samples was assessed by immunohistochemistry (IHC), and the mRNA abundance of IGF2BP1 and INHBA was analyzed with TCGA datasets and by RNA in situ hybridization (RISH). The methylation level of the\n                      <jats:italic>IGF2BP1<\/jats:italic>\n                      promoter region was detected by methylation-specific PCR (MSP-PCR). Cell viability, migration, invasion and in vivo metastasis assays were performed to explore the roles of IGF2BP1 overexpression in ESCC. RNA immunoprecipitation sequencing (RIP-seq) and mass spectrometry were applied to identify the target RNAs and interacting proteins of IGF2BP1, respectively. RIP-PCR, RNA pulldown, immunofluorescence (IF), gene-specific m\n                      <jats:sup>6<\/jats:sup>\n                      A PCR and RNA stability assays were used to uncover the molecular mechanisms underlying the malignant phenotypes of ESCC cells caused by IGF2BP1 dysregulation. BTYNB, a small molecular inhibitor of IGF2BP1, was evaluated for its inhibitory effect on the malignant phenotypes of ESCC cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IGF2BP1 overexpression was detected in ESCC tissues and associated with the depth of tumor invasion. In addition, IGF2BP1 mRNA expression in ESCC cells was negatively correlated with the level of its promoter methylation. Knockdown of IGF2BP1 inhibited ESCC cell invasion and migration as well as tumor metastasis. Mechanistically, we observed that IGF2BP1 bound and stabilized INHBA mRNA and then resulted in higher protein expression of INHBA, leading to the activation of Smad2\/3 signaling, thus promoting malignant phenotypes. The mRNA level of INHBA was upregulated in ESCC tissues as well. Furthermore, IGF2BP1 interacted with G3BP stress granule assembly factor 1 (G3BP1). Knockdown of G3BP1 also down-regulated the INHBA-Smad2\/3 signaling. BTYNB abolished this activated signaling and significantly attenuated the malignant phenotypes of ESCC cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated expression of IGF2BP1 is a frequent event in ESCC tissues and might be a candidate biomarker for the disease. IGF2BP1 overexpression promotes the invasion and migration of ESCC cells by activating the INHBA-Smad2\/3 pathway, providing a potential therapeutic target for ESCC patients with high expression of IGF2BP1.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40164-023-00429-8","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T09:03:04Z","timestamp":1693299784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells"],"prefix":"10.1186","volume":"12","author":[{"given":"Juan-Juan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Xiong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jie","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"issue":"5","key":"429_CR1","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","volume":"6","author":"H Zeng","year":"2018","unstructured":"Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555\u2013e67.","journal-title":"Lancet Glob Health"},{"issue":"37","key":"429_CR2","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1038\/onc.2008.141","volume":"27","author":"I Elcheva","year":"2008","unstructured":"Elcheva I, Tarapore RS, Bhatia N, Spiegelman VS. Overexpression of mRNA-binding protein CRD-BP in malignant melanomas. Oncogene. 2008;27(37):5069\u201374.","journal-title":"Oncogene"},{"issue":"Pt 1","key":"429_CR3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1242\/jcs.086132","volume":"125","author":"W Gu","year":"2012","unstructured":"Gu W, Katz Z, Wu B, Park HY, Li D, Lin S, et al. Regulation of local expression of cell adhesion and motility-related mRNAs in breast cancer cells by IMP1\/ZBP1. J Cell Sci. 2012;125(Pt 1):81\u201391.","journal-title":"J Cell Sci"},{"issue":"3","key":"429_CR4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/15476286.2020.1812894","volume":"18","author":"N Bley","year":"2021","unstructured":"Bley N, Schott A, Muller S, Misiak D, Lederer M, Fuchs T, et al. IGF2BP1 is a targetable SRC\/MAPK-dependent driver of invasive growth in ovarian cancer. RNA Biol. 2021;18(3):391\u2013403.","journal-title":"RNA Biol"},{"issue":"54","key":"429_CR5","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1038\/sj.onc.1210563","volume":"26","author":"M Kobel","year":"2007","unstructured":"Kobel M, Weidensdorfer D, Reinke C, Lederer M, Schmitt WD, Zeng K, et al. Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma. Oncogene. 2007;26(54):7584\u20139.","journal-title":"Oncogene"},{"issue":"18","key":"429_CR6","doi-asserted-by":"crossref","first-page":"18453","DOI":"10.18632\/aging.103811","volume":"12","author":"L Fan","year":"2020","unstructured":"Fan L, Lin Y, Lei H, Shu G, He L, Yan Z, et al. A newly defined risk signature, consisting of three m(6)a RNA methylation regulators, predicts the prognosis of ovarian cancer. Aging. 2020;12(18):18453\u201375.","journal-title":"Aging"},{"key":"429_CR7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.omtn.2020.12.020","volume":"23","author":"XL Zhang","year":"2021","unstructured":"Zhang XL, Li KJ, Feng JX, Liu GJ, Feng YL. Blocking the IGF2BP1-promoted glucose metabolism of colon cancer cells via direct de-stabilizing mRNA of the LDHA enhances anticancer effects. Mol Ther Nucleic Acids. 2021;23:835\u201346.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"429_CR8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ijc.22716","volume":"121","author":"E Dimitriadis","year":"2007","unstructured":"Dimitriadis E, Trangas T, Milatos S, Foukas PG, Gioulbasanis I, Courtis N, et al. Expression of oncofetal RNA-binding protein CRD-BP\/IMP1 predicts clinical outcome in colon cancer. Int J Cancer. 2007;121(3):486\u201394.","journal-title":"Int J Cancer"},{"issue":"9","key":"429_CR9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41419-020-02967-z","volume":"11","author":"J Zhang","year":"2020","unstructured":"Zhang J, Hu K, Yang YQ, Wang Y, Zheng YF, Jin Y, et al. LIN28B-AS1-IGF2BP1 binding promotes hepatocellular carcinoma cell progression. Cell Death Dis. 2020;11(9):741.","journal-title":"Cell Death Dis"},{"issue":"5","key":"429_CR10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/hep.26537","volume":"58","author":"M Hammerle","year":"2013","unstructured":"Hammerle M, Gutschner T, Uckelmann H, Ozgur S, Fiskin E, Gross M, et al. Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1). Hepatology. 2013;58(5):1703\u201312.","journal-title":"Hepatology"},{"issue":"2 Pt 1","key":"429_CR11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1158\/1078-0432.CCR-06-1297","volume":"13","author":"T Kato","year":"2007","unstructured":"Kato T, Hayama S, Yamabuki T, Ishikawa N, Miyamoto M, Ito T, et al. Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer. Clin Cancer Res. 2007;13(2 Pt 1):434\u201342.","journal-title":"Clin Cancer Res"},{"key":"429_CR12","doi-asserted-by":"crossref","first-page":"108581","DOI":"10.1016\/j.abb.2020.108581","volume":"693","author":"J Zhang","year":"2020","unstructured":"Zhang J, Luo W, Chi X, Zhang L, Ren Q, Wang H, et al. IGF2BP1 silencing inhibits proliferation and induces apoptosis of high glucose-induced non-small cell lung cancer cells by regulating Netrin-1. Arch Biochem Biophys. 2020;693:108581.","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"429_CR13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-018-0628-y","volume":"11","author":"X Huang","year":"2018","unstructured":"Huang X, Zhang H, Guo X, Zhu Z, Cai H, Kong X. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer. J Hematol Oncol. 2018;11(1):88.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"429_CR14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40164-021-00247-w","volume":"10","author":"J Zhang","year":"2021","unstructured":"Zhang J, He X, Wan Y, Zhang H, Tang T, Zhang M, et al. CD44 promotes hepatocellular carcinoma progression via upregulation of YAP. Exp Hematol Oncol. 2021;10(1):54.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"429_CR15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-021-01111-4","volume":"14","author":"SE Ahmadi","year":"2021","unstructured":"Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol. 2021;14(1):121.","journal-title":"J Hematol Oncol"},{"issue":"7481","key":"429_CR16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X Wang","year":"2014","unstructured":"Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117\u201320.","journal-title":"Nature"},{"issue":"3","key":"429_CR17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","volume":"20","author":"H Huang","year":"2018","unstructured":"Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285\u201395.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"429_CR18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40164-021-00234-1","volume":"10","author":"J Huang","year":"2021","unstructured":"Huang J, Shao Y, Gu W. Function and clinical significance of N6-methyladenosine in digestive system tumours. Exp Hematol Oncol. 2021;10(1):40.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"429_CR19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-022-00298-7","volume":"11","author":"Z Fang","year":"2022","unstructured":"Fang Z, Mei W, Qu C, Lu J, Shang L, Cao F, et al. Role of m6A writers, erasers and readers in cancer. Exp Hematol Oncol. 2022;11(1):45.","journal-title":"Exp Hematol Oncol"},{"issue":"15","key":"429_CR20","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1007\/s00018-012-1186-z","volume":"70","author":"JL Bell","year":"2013","unstructured":"Bell JL, Wachter K, Muhleck B, Pazaitis N, Kohn M, Lederer M, et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci. 2013;70(15):2657\u201375.","journal-title":"Cell Mol Life Sci"},{"issue":"23","key":"429_CR21","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1158\/1078-0432.CCR-14-0583","volume":"20","author":"F Shi","year":"2014","unstructured":"Shi F, Shang L, Pan BQ, Wang XM, Jiang YY, Hao JJ, et al. Calreticulin promotes migration and invasion of esophageal cancer cells by upregulating neuropilin-1 expression via STAT5A. Clin Cancer Res. 2014;20(23):6153\u201362.","journal-title":"Clin Cancer Res"},{"issue":"37","key":"429_CR22","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/onc.2016.17","volume":"35","author":"YY Jiang","year":"2016","unstructured":"Jiang YY, Shang L, Shi ZZ, Zhang TT, Ma S, Lu CC, et al. Microtubule-associated protein 4 is an important regulator of cell invasion\/migration and a potential therapeutic target in esophageal squamous cell carcinoma. Oncogene. 2016;35(37):4846\u201356.","journal-title":"Oncogene"},{"key":"429_CR23","doi-asserted-by":"crossref","unstructured":"Zhu Y, Jin L, Shi R, Li J, Wang Y, Zhang L et al. The long noncoding RNA glycoLINC assembles a lower glycolytic metabolon to promote glycolysis. Mol Cell 2022;82(3): 542 \u2013 54 e6.","DOI":"10.1016\/j.molcel.2021.11.017"},{"key":"429_CR24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0076-6879(08)02617-7","volume":"448","author":"CY Chen","year":"2008","unstructured":"Chen CY, Ezzeddine N, Shyu AB. Messenger RNA half-life measurements in mammalian cells. Methods Enzymol. 2008;448:335\u201357.","journal-title":"Methods Enzymol"},{"issue":"2","key":"429_CR25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.stem.2017.11.016","volume":"22","author":"H Weng","year":"2018","unstructured":"Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, et al. METTL14 inhibits hematopoietic Stem\/Progenitor differentiation and promotes Leukemogenesis via mRNA m(6)a modification. Cell Stem Cell. 2018;22(2):191\u2013205. e9.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"429_CR26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675\u20138.","journal-title":"Nat Biotechnol"},{"key":"429_CR27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13072-015-0014-8","volume":"8","author":"A Diez-Villanueva","year":"2015","unstructured":"Diez-Villanueva A, Mallona I, Peinado MA. Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. Epigenetics Chromatin. 2015;8:22.","journal-title":"Epigenetics Chromatin"},{"issue":"6220","key":"429_CR28","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.","journal-title":"Science"},{"issue":"5","key":"429_CR29","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1074\/mcp.M600346-MCP200","volume":"6","author":"L Jonson","year":"2007","unstructured":"Jonson L, Vikesaa J, Krogh A, Nielsen LK, Hansen T, Borup R, et al. Molecular composition of IMP1 ribonucleoprotein granules. Mol Cell Proteomics. 2007;6(5):798\u2013811.","journal-title":"Mol Cell Proteomics"},{"issue":"2","key":"429_CR30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.celrep.2014.03.015","volume":"7","author":"L Jonson","year":"2014","unstructured":"Jonson L, Christiansen J, Hansen TVO, Vikesa J, Yamamoto Y, Nielsen FC. IMP3 RNP safe houses prevent miRNA-directed HMGA2 mRNA decay in cancer and development. Cell Rep. 2014;7(2):539\u201351.","journal-title":"Cell Rep"},{"issue":"3","key":"429_CR31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/1087057113499633","volume":"19","author":"L Mahapatra","year":"2014","unstructured":"Mahapatra L, Mao C, Andruska N, Zhang C, Shapiro DJ. High-throughput fluorescence anisotropy screen for inhibitors of the oncogenic mRNA binding protein, IMP-1. J Biomol Screen. 2014;19(3):427\u201336.","journal-title":"J Biomol Screen"},{"issue":"5","key":"429_CR32","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.tranon.2017.07.008","volume":"10","author":"L Mahapatra","year":"2017","unstructured":"Mahapatra L, Andruska N, Mao C, Le J, Shapiro DJ. A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits Melanoma and Ovarian Cancer Cell Proliferation. Transl Oncol. 2017;10(5):818\u201327.","journal-title":"Transl Oncol"},{"issue":"15","key":"429_CR33","doi-asserted-by":"crossref","first-page":"8576","DOI":"10.1093\/nar\/gkaa653","volume":"48","author":"S Muller","year":"2020","unstructured":"Muller S, Bley N, Busch B, Glass M, Lederer M, Misiak C, et al. The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer. Nucleic Acids Res. 2020;48(15):8576\u201390.","journal-title":"Nucleic Acids Res"},{"key":"429_CR34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2014.07.006","volume":"29","author":"M Lederer","year":"2014","unstructured":"Lederer M, Bley N, Schleifer C, Huttelmaier S. The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. Semin Cancer Biol. 2014;29:3\u201312.","journal-title":"Semin Cancer Biol"},{"issue":"22","key":"429_CR35","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1101\/gad.287540.116","volume":"30","author":"N Degrauwe","year":"2016","unstructured":"Degrauwe N, Suva ML, Janiszewska M, Riggi N, Stamenkovic I. IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer. Genes Dev. 2016;30(22):2459\u201374.","journal-title":"Genes Dev"},{"key":"429_CR36","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2147\/CMAR.S160186","volume":"10","author":"S Lyu","year":"2018","unstructured":"Lyu S, Jiang C, Xu R, Huang Y, Yan S. INHBA upregulation correlates with poorer prognosis in patients with esophageal squamous cell carcinoma. Cancer Manag Res. 2018;10:1585\u201396.","journal-title":"Cancer Manag Res"},{"key":"429_CR37","doi-asserted-by":"crossref","first-page":"15007","DOI":"10.1038\/npjbcancer.2015.7","volume":"1","author":"M Bashir","year":"2015","unstructured":"Bashir M, Damineni S, Mukherjee G, Kondaiah P. Activin-A signaling promotes epithelial-mesenchymal transition, invasion, and metastatic growth of breast cancer. NPJ Breast Cancer. 2015;1:15007.","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"429_CR38","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.3892\/or.2013.2761","volume":"30","author":"M Okano","year":"2013","unstructured":"Okano M, Yamamoto H, Ohkuma H, Kano Y, Kim H, Nishikawa S, et al. Significance of INHBA expression in human colorectal cancer. Oncol Rep. 2013;30(6):2903\u20138.","journal-title":"Oncol Rep"},{"issue":"1","key":"429_CR39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12032-010-9766-y","volume":"29","author":"Q Wang","year":"2012","unstructured":"Wang Q, Wen YG, Li DP, Xia J, Zhou CZ, Yan DW, et al. Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol. 2012;29(1):77\u201383.","journal-title":"Med Oncol"},{"issue":"4","key":"429_CR40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1593\/neo.81582","volume":"11","author":"CW Seder","year":"2009","unstructured":"Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, et al. Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia. 2009;11(4):388\u201396.","journal-title":"Neoplasia"},{"issue":"4","key":"429_CR41","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/jso.23836","volume":"111","author":"HY Lee","year":"2015","unstructured":"Lee HY, Li CC, Huang CN, Li WM, Yeh HC, Ke HL, et al. INHBA overexpression indicates poor prognosis in urothelial carcinoma of urinary bladder and upper tract. J Surg Oncol. 2015;111(4):414\u201322.","journal-title":"J Surg Oncol"},{"issue":"4","key":"429_CR42","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/JTO.0b013e31819c791a","volume":"4","author":"CW Seder","year":"2009","unstructured":"Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, et al. INHBA overexpression promotes cell proliferation and may be epigenetically regulated in esophageal adenocarcinoma. J Thorac Oncol. 2009;4(4):455\u201362.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"429_CR43","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3390\/ijms23042072","volume":"23","author":"CC Kao","year":"2022","unstructured":"Kao CC, Chang YL, Liu HY, Wu ST, Meng E, Cha TL, et al. DNA hypomethylation is Associated with the overexpression of INHBA in Upper Tract Urothelial Carcinoma. Int J Mol Sci. 2022;23(4):2072.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"429_CR44","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2014.04.033","volume":"54","author":"SF Mitchell","year":"2014","unstructured":"Mitchell SF, Parker R. Principles and properties of eukaryotic mRNPs. Mol Cell. 2014;54(4):547\u201358.","journal-title":"Mol Cell"},{"issue":"1","key":"429_CR45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1083\/jcb.201408092","volume":"209","author":"A Aulas","year":"2015","unstructured":"Aulas A, Caron G, Gkogkas CG, Mohamed NV, Destroismaisons L, Sonenberg N, et al. G3BP1 promotes stress-induced RNA granule interactions to preserve polyadenylated mRNA. J Cell Biol. 2015;209(1):73\u201384.","journal-title":"J Cell Biol"},{"key":"429_CR46","doi-asserted-by":"crossref","unstructured":"Meyer C, Garzia A, Morozov P, Molina H, Tuschl T. The G3BP1-Family-USP10 deubiquitinase complex rescues ubiquitinated 40S subunits of Ribosomes stalled in translation from lysosomal degradation. Mol Cell 2020;77(6): 1193 \u2013 205 e5.","DOI":"10.1016\/j.molcel.2019.12.024"},{"issue":"7095","key":"429_CR47","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nature04839","volume":"441","author":"FK Noubissi","year":"2006","unstructured":"Noubissi FK, Elcheva I, Bhatia N, Shakoori A, Ougolkov A, Liu J, et al. CRD-BP mediates stabilization of betaTrCP1 and c-myc mRNA in response to beta-catenin signalling. Nature. 2006;441(7095):898\u2013901.","journal-title":"Nature"},{"issue":"10","key":"429_CR48","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1947601910395581","volume":"1","author":"FK Noubissi","year":"2010","unstructured":"Noubissi FK, Nikiforov MA, Colburn N, Spiegelman VS. Transcriptional regulation of CRD-BP by c-myc: implications for c-myc functions. Genes Cancer. 2010;1(10):1074\u201382.","journal-title":"Genes Cancer"},{"issue":"8","key":"429_CR49","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/ijc.26190","volume":"130","author":"B Boyerinas","year":"2012","unstructured":"Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M, et al. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer. 2012;130(8):1787\u201397.","journal-title":"Int J Cancer"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-023-00429-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T08:46:49Z","timestamp":1700297209000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-023-00429-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1186\/s40164-023-00429-8","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"10 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of National Cancer Center\/Cancer Institute (Hospital), CAMS & PUMC (No. 16\u2013171\/1250). All the animal experiments were approved by the Animal Center of the Institute of National Cancer Center\/Cancer Hospital, CAMS & PUMC (NCC2019A016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}